Siemens with the formation of its Siemens Medical Solutions Molecular
Imaging division, through a series of business combinations, has molecular plans that are expected to change the way diseases
are treated and diagnosed. Behind Siemens business strategy is a scientific premise that states that the onset of disease
is preceded with observable characteristic changes at the molecular and cellular level. The goal of molecular imaging is to
use molecules and cells to diagnose a disease at the very earliest stage. According to Siemens, "With molecular imaging,
earlier diagnosis of disease will be possible, since changes at the molecular level always precede anatomical structural changes.”
Molecular imaging systems may eventually also significantly reduce
health costs. According to Erich Reinhardt, Ph.D., President and CEO, Siemens Medical Solutions, "By strengthening our leadership
position in identifying disease earlier at the molecular level, we continue to transform the delivery of healthcare by improving
patient care while reducing costs."
